Advanced search
Publication Cover
Acta Cardiologica Volume 79, 2024 - Issue 2
Submit an article Journal homepage
66
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Very long versus overlapping drug eluting stents for the management of long coronary artery lesions

Ahmed Mohamed NaguibDepartment of Cardiology, Alexandria University, Alexandria, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6092-0584
ORCID Icon,
Mohamed Ahmed SobhiDepartment of Cardiology, Alexandria University, Alexandria, Egypt
,
Amr ZakiDepartment of Cardiology, Alexandria University, Alexandria, Egypt
&
Ahmed Mahmoud El AmrawyDepartment of Cardiology, Alexandria University, Alexandria, Egypt
Pages 187-193 | Received 15 Sep 2023, Accepted 26 Nov 2023, Published online: 12 Dec 2023

References

  • Bouras G, Jhamnani S, Ng VG, et al. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheter Cardiovasc Interv. 2017;89(6):984–991. doi: 10.1002/ccd.26711.
  • Mohamed MO, Polad J, Hildick-Smith D, et al. Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, ­multicentre e-ultimaster registry. EuroIntervention. 2020;16(7):603–612. doi: 10.4244/EIJ-D-20-00361.
  • Kong MG, Han J-K, Kang J-H, et al. Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. EuroIntervention. 2021;16(16):1318–1325. doi: 10.4244/EIJ-D-19-00296.
  • Piccolo R, Giustino G, Mehran R, et al. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386(9994):702–713. doi: 10.1016/S0140-6736(15)61220-X.
  • Choi IJ, Koh Y-S, Lim S, et al. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. Am J Cardiol. 2014;113(3):457–464. doi: 10.1016/j.amjcard.2013.10.029.
  • Hara H, Ono M, Kawashima H, et al. Impact of stent length and diameter on 10‐year mortality in the SYNTAXES trial. Catheter Cardiovasc Interv. 2021;98(3):E379–E387. doi: 10.1002/ccd.29721.
  • Valero E, Consuegra-Sanchez L, Minana G, et al. Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions. EuroIntervention. 2018;13(13):1591–1594. doi: 10.4244/EIJ-D-17-00616.
  • Jain RK, Chakravarthi P, Shetty R, et al. One-year outcomes of a BioMime™ sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: the meriT-3 study. Indian Heart J. 2016;68(5):599–603. doi: 10.1016/j.ihj.2016.09.007.
  • Schampaert E, Moses JW, Schofer J, et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006;98(1):36–41. doi: 10.1016/j.amjcard.2006.01.049.
  • Stone GW, Ellis SG, Cox DA, et al. One-year clinical ­results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109(16):1942–1947. doi: 10.1161/01.CIR.0000127110.49192.72.
  • Caputo RP, Goel A, Pencina M, et al. Impact of drug eluting stent length on outcomes of percutaneous ­coronary intervention (from the EVENT registry). Am J Cardiol. 2012;110(3):350–355. doi: 10.1016/j.amjcard.2012.03.031.
  • Räber L, Jüni P, Löffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in ­patients undergoing drug-eluting stent implantation. J Am Coll Cardiol. 2010;55(12):1178–1188. doi: 10.1016/j.jacc.2009.11.052.
  • Balakrishnan B, Tzafriri AR, Seifert P, et al. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation. 2005;111(22):2958–2965. doi: 10.1161/CIRCULATIONAHA.104.512475.
  • Amirzadegan A, Hasanabadi M, Saadatagah S, et al. Single long stents versus overlapping multiple stents in the management of very long coronary lesions: comparisons of procedures and clinical outcomes. J Tehran Heart Cent. 2019;14(3):94–102.
  • Jurado-Román A, Abellán-Huerta J, Requena JA, et al. Comparison of clinical outcomes between very long stents and overlapping stents for the treatment of diffuse coronary disease in real clinical practice. Cardiovasc Revasc Med. 2019;20(8):681–686. doi: 10.1016/j.carrev.2018.09.009.
  • Sim HW, Thong EH, Loh PH, et al. Treating very long coronary artery lesions in the contemporary drug-eluting-stent era: single long 48 mm stent versus two overlapping stents showed comparable clinical outcomes. Cardiovasc Revasc Med. 2020;21(9):1115–1118. doi: 10.1016/j.carrev.2020.02.005.
  • Negreira-Caamano M, Abellan-Huerta J, Lozano-Ruiz-Poveda F, et al. Percutaneous intervention in diffuse coronary disease: overlapping versus single very long stent technique. Results from the OVERLONG registry. Angiology. 2021;72(10):979–985. doi: 10.1177/00033197211014686.
  • Hong SJ, Mintz GS, Ahn CM, et al. Effect of intravascular Ultrasound-Guided drug-eluting stent implantation: 5-Year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13(1):62–71. doi: 10.1016/j.jcin.2019.09.033.
  • Otake H, Honda Y, Yamasaki M, et al. Vascular response to overlapping everolimus-eluting stents. - comparison with paclitaxel-eluting stents. Circ J. 2010;74(5):1023–1025. doi: 10.1253/circj.cj-10-0052.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.